Enterprise Value
330.9M
Cash
505.9M
Avg Qtr Burn
-163.5M
Short % of Float
52.96%
Insider Ownership
0.60%
Institutional Own.
70.61%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Approved Update | ||
Nuvaxovid (NVX-CoV2373) Details COVID-19 | Approved Update | |
Novavax COVID-NanoFlu combination (NVX-CoV2373) + Matrix-M™ Details Influenza, COVID-19 | Phase 3 Data readout | |
Phase 3 Data readout | ||
NanoFlu vaccine Details Influenza | Phase 2 Initiation | |
RSV Vaccine Details Respiratory syncytial virus | Failed Discontinued | |
RSV Vaccine Details Respiratory syncytial virus | Failed Discontinued | |
RSV Vaccine Details Respiratory syncytial virus | Failed Discontinued |